Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

È­ÇÐÀûÀ¸·Î À¯µµÇÑ ¹é¼­ °£¾Ï¿¡¼­ TGF-beta1 ¹× TGF-beta type II receptorÀÇ ¹ßÇö Expression of TGF-beta1 and TGF-beta type II Receptor in Chemically Induced Hepatocarcinogenesis of the Rat

´ëÇѺ´¸®ÇÐȸÁö 2003³â 37±Ç 2È£ p.121 ~ 128
¹ÚµµÀ±, ¹Ú°­¿ì, ¼­°­¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
¹ÚµµÀ± ( Park Do-Youn ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

¹Ú°­¿ì ( Park Kang-Woo ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¼­°­¼® ( Suh Kang-Suek ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: Transforming growth factor (TGF)-beta1 inhibits hepatocyte proliferation by inducing apoptosis. Expression of TGF-beta1 is tightly associated with the TGF-beta type II receptor (TGR2) expression level, and has been regarded as an important change of TGF-beta1 and TGR2 during hepatocarcinogenesis. We investigated the gene expressions and protein localizations of TGF-beta1 and TGR2 in chemical hepatocarcinogenesis.

Methods: Solt and Farber¡¯s method was used as the chemical hepatocarcinogenesis model of the rat. Northern blot analyses and immunohistochemistry for TGF-beta1 and TGR2 were performed to investigate the gene expressions and protein localizations, respectively.

Results: The Northern blot analyses showed a slight increase of TGF-beta1 transcripts one month after partial hepatectomy, which is more than in sham operated control liver, and a decrease of transcripts for TGR2 two months after partial hepatectomy. The number of TGF-beta1-positive preneoplastic hepatocytes was increased and correlated with the increase of the number of TGR2 negative hepatocytes or reduction of expressions of TGR2 in preneoplastic lesions. HCC tissues showed an increase of TGF-beta1 protein expressions and a decrease of TGR2 compared to the adjacent liver parenchyme.

Conclusion: Our data suggest that down regulation of TGR2 in reneoplastic lesions and HCC might contribute to the resistance to the growth inhibitory effects of TGF-beta1.

Å°¿öµå

Carcinoma;Hepatocellular;Transforming Growth Factor beta;Blotting;Northern;Immunohistochemistry;Rats

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS